Phase 2b Survival Data of R1 Resection Subjects Presented at ESMO 14th World Congress on Gastrointestinal Cancer BARCELONA, Spain, June 27, 2012 – GlobeImmune, Inc., today announced that GI-4000 in combination with gemcitabine showed evidence of an improvement in overall survival … Continue reading
GlobeImmune’s GI-4000 in Combination with Gemcitabine Following Surgery Shows Evidence of an Improvement in Survival in a Phase 2b Clinical Trial with Ras Mutation Positive Pancreas Cancer
June 27, 2012